Sarepta Therapeutics soars 31% as FDA committee supports gene therapy for Duchenne muscular dystrophy. Analysts have a “moderate buy” rating on the stock.
Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy
You may also like
Latest News
American Airlines just added 30 new routes to a single location (it’s that popular)
As part of their route-planning for the year ahead, airlines will typically launch ...
Latest News
Crypto Market Braces For Dramatic Shift: Analyst’s Predictions About Solana, Chainlink, Avalanche Send Shockwaves
A pseudonymous cryptocurrency analyst issued a warning to investors and traders in the digital ...
Latest News
Salesforce Sees Strong Opportunity From Continued AI Adoption; 10 Of 12 Analysts Raise Their Forecasts
Shares of Salesforce Inc (NYSE: CRM) were climbing in early trading on Thursday after the ...
